Presentation is loading. Please wait.

Presentation is loading. Please wait.

Hierarchical clustering of non-classical monocytes from patients and controls, with tracks indicating individuals, IFN score, SLEDAI score and prednisone.

Published byMaud Sherman Modified over 5 years ago

Similar presentations

Presentation on theme: "Hierarchical clustering of non-classical monocytes from patients and controls, with tracks indicating individuals, IFN score, SLEDAI score and prednisone."— Presentation transcript:

1 Hierarchical clustering of non-classical monocytes from patients and controls, with tracks indicating individuals, IFN score, SLEDAI score and prednisone usage. Hierarchical clustering of non-classical monocytes from patients and controls, with tracks indicating individuals, IFN score, SLEDAI score and prednisone usage. Each single cell forms a single row, and each column corresponds to an individual gene. All non-classical cells and genes are shown. Lower right corner inset shows heat map colour scheme key, with units indicating the delta CT values for each transcript. Colour codes for the data columns: Subject—white: healthy subjects; each colour represents one subject with SLE; interferon (IFN) score—darker green means higher IFN score; systemic lupus erythematosus disease activity index (SLEDAI) score—red: SLEDAI ≥10; pink: SLEDAI 3 to 6; white: SLEDAI 0 to 2; prednisone—dark blue: 20 mg/day; light blue: less than 10 mg/day; white: no prednisone. Black horizontal bars demarcate groups of cells that correspond to controls, high IFN, high SLEDAI and high-dose prednisone. Zhongbo Jin et al. Lupus Sci Med 2017;4:e000202 ©2017 by Lupus Foundation of America

Download ppt "Hierarchical clustering of non-classical monocytes from patients and controls, with tracks indicating individuals, IFN score, SLEDAI score and prednisone."

Similar presentations

Proportion of patients that met the SRI-5 response criteria (A and C) and reasons for non-response (B and D) in trial 1 (A and B) and trial 2 (C and D).

Proportion of patients that met the SRI-5 response criteria (A and C) and reasons for non-response (B and D) in trial 1 (A and B) and trial 2 (C and D).
Fig. 8. Recurrent copy number amplification of BRD4 gene was observed across common cancers. Recurrent copy number amplification of BRD4 gene was observed.

Fig. 8. Recurrent copy number amplification of BRD4 gene was observed across common cancers. Recurrent copy number amplification of BRD4 gene was observed.
Anifrolumab inhibits type I interferon (IFN)-induced IFN-stimulated response element (ISRE) signalling. Anifrolumab inhibits type I interferon (IFN)-induced.

Anifrolumab inhibits type I interferon (IFN)-induced IFN-stimulated response element (ISRE) signalling. Anifrolumab inhibits type I interferon (IFN)-induced.
Time between systemic lupus erythematosus (SLE) and haematological malignancy diagnoses. Time between systemic lupus erythematosus (SLE) and haematological.

Time between systemic lupus erythematosus (SLE) and haematological malignancy diagnoses. Time between systemic lupus erythematosus (SLE) and haematological.
Host transcriptional profiling distinguishes patients with acute LRTI (LRTI+C+M) from those with noninfectious acute respiratory illness (no-LRTI). Host.

Host transcriptional profiling distinguishes patients with acute LRTI (LRTI+C+M) from those with noninfectious acute respiratory illness (no-LRTI). Host.
Time course for laboratory parameters of a patient with systemic lupus erythematosus prior and during bortezomib therapy (arrow). Time course for laboratory.

Time course for laboratory parameters of a patient with systemic lupus erythematosus prior and during bortezomib therapy (arrow). Time course for laboratory.
Fig. 2 TLR8 is aberrantly expressed on pDCs from SSc patients.

Fig. 2 TLR8 is aberrantly expressed on pDCs from SSc patients.
Volume 72, Issue 7, Pages (October 2007)

Volume 72, Issue 7, Pages (October 2007)
Correlation between disease activity and phospho-H2AX levels at G0/G1, S and G2 cell-cycle phases in primary CD3+ T cells and monocytes from patients with.

Correlation between disease activity and phospho-H2AX levels at G0/G1, S and G2 cell-cycle phases in primary CD3+ T cells and monocytes from patients with.
Mean Safety of Estrogens in Lupus Erythematosus National Assessment–Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) score at the last.

Mean Safety of Estrogens in Lupus Erythematosus National Assessment–Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) score at the last.
Immunohistochemistry staining of interferon (IFN)-λ in renal tissue.

Immunohistochemistry staining of interferon (IFN)-λ in renal tissue.
Tfr cells’ transcriptomic profile distinguishes them from Treg and Tfh cells. Tfr cells’ transcriptomic profile distinguishes them from Treg and Tfh cells.

Tfr cells’ transcriptomic profile distinguishes them from Treg and Tfh cells. Tfr cells’ transcriptomic profile distinguishes them from Treg and Tfh cells.
Bettina Heidecker et al. BTS 2016;1:

Bettina Heidecker et al. BTS 2016;1:
(A) Phospho-H2AX levels are significantly increased in CD4+ T cells, CD8+ T cells and monocytes from SLE compared with those from healthy controls (p=2.16×10−4,

(A) Phospho-H2AX levels are significantly increased in CD4+ T cells, CD8+ T cells and monocytes from SLE compared with those from healthy controls (p=2.16×10−4,
Patient organoids respond more diverse to drugs and with lower therapeutic potential than 2D cultured patient cells Patient organoids respond more diverse.

Patient organoids respond more diverse to drugs and with lower therapeutic potential than 2D cultured patient cells Patient organoids respond more diverse.
Figure 1 Reduced pedigrees of the 11 PFBC families with MYORG mutations. Arrow = proband; asterisk = DNA available; ... Figure 1 Reduced pedigrees of the.

Figure 1 Reduced pedigrees of the 11 PFBC families with MYORG mutations. Arrow = proband; asterisk = DNA available; ... Figure 1 Reduced pedigrees of the.
Lupus Foundation of America-Rapid Evaluation of Activity in Lupus (LFA-REAL) comprised seven anchored Visual Analogue Scales (0–100 mm each) and can describe.

Lupus Foundation of America-Rapid Evaluation of Activity in Lupus (LFA-REAL) comprised seven anchored Visual Analogue Scales (0–100 mm each) and can describe.
Transcriptome analyses of four regions of the mouse brain.

Transcriptome analyses of four regions of the mouse brain.
Network modules correspond to known and novel functional distinctions between neuronal subtypes. Network modules correspond to known and novel functional.

Network modules correspond to known and novel functional distinctions between neuronal subtypes. Network modules correspond to known and novel functional.
Deficiency of TLR9 promotes more severe renal inflammation in imiquimod-induced autoimmunity. Deficiency of TLR9 promotes more severe renal inflammation.

Deficiency of TLR9 promotes more severe renal inflammation in imiquimod-induced autoimmunity. Deficiency of TLR9 promotes more severe renal inflammation.

Similar presentations

Ads by Google